荃信生物-B(02509.HK) 公布,联交所已于3月13日授出上市批准。上市批准并不表示经转换H股已取得上市所需的所有批准及通过上市所需的所有程序。转换及上市将涉及合共三名持有1,732.24万股已发行内资股的参与股东,于转换及上市后,彼等将合共持有公司已发行H股总数约7.8%。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source Link荃信生物-B(02509.HK) 公布,联交所已于3月13日授出上市批准。上市批准并不表示经转换H股已取得上市所需的所有批准及通过上市所需的所有程序。转换及上市将涉及合共三名持有1,732.24万股已发行内资股的参与股东,于转换及上市后,彼等将合共持有公司已发行H股总数约7.8%。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.